Analyst Ratings For Onconova Therapeutics (NASDAQ:ONTX)
Today, HC Wainwright reiterated its Buy rating on Onconova Therapeutics (NASDAQ:ONTX) with a price target of $7.50.
Some recent analyst ratings include
- 3/1/2018-HC Wainwright Reiterated Rating of Buy .
- 1/17/2018-Maxim Group was Downgraded by analysts at Maxim Group from a “Buy ” rating to a ” Hold” rating.
- 7/25/2017-Dawson James Reiterated Rating of Buy.
- 4/27/2017-Laidlaw initiated coverage with a Buy rating.
Recent Insider Trading Activity For Onconova Therapeutics (NASDAQ:ONTX)
Onconova Therapeutics (NASDAQ:ONTX) has insider ownership of 27.30% and institutional ownership of 25.27%.
- On 2/8/2018 683 Capital Management, Llc, Major Shareholder, bought 200,000 with an average share price of $1.04 per share and the total transaction amounting to $208,000.00.
- On 4/26/2017 E Premkumar Reddy, Director, bought 119,048 with an average share price of $2.10 per share and the total transaction amounting to $250,000.80.
- On 4/26/2017 Mark Patrick Guerin, CFO, bought 1,429 with an average share price of $2.10 per share and the total transaction amounting to $3,000.90.
- On 4/26/2017 Ramesh Kumar, Insider, bought 23,810 with an average share price of $2.10 per share and the total transaction amounting to $50,001.00.
- On 2/21/2014 & Jane Hoffman 2013 De Michael, major shareholder, bought 143,480 with an average share price of $8.47 per share and the total transaction amounting to $1,215,275.60.
- On 2/10/2014 Ramesh Kumar, CEO, sold 33,543 with an average share price of $15.07 per share and the total transaction amounting to $505,493.01.
- On 2/3/2014 Ramesh Kumar, CEO, sold 60,000 with an average share price of $15.05 per share and the total transaction amounting to $903,000.00.
Recent Trading Activity for Onconova Therapeutics (NASDAQ:ONTX)
Shares of Onconova Therapeutics closed the previous trading session at 1.12 up +0.03 3.21% with shares trading hands.